News

Sunovion Pharmaceuticals, a biopharma focused on the development of medical solutions for psychiatric, neurological, and respiratory conditions, recently presented the results of two clinical outcome research studies that investigated the treatment adequacy and inhaler use in chronic obstructive pulmonary disease (COPD) patients. The poster presentation sessions reporting data from…

Therabron Therapeutics, a biotech company developing a novel class of drugs based on the naturally occurring secretoglobin proteins, announced a new research program to develop a series of new isoforms of their lead candidate, the recombinant human CC10 protein. Therabron plans to provide treatment for a range of orphan and more commonplace…

A new study investigated the differences in the services provided to patients with chronic obstructive pulmonary disease (COPD) by doctors and by nurse practitioners and physician assistants. The study was conducted by researchers from The University of Texas Medical Branch (UTMB) at Galveston, and published in the scientific periodical PLOS…

Physical activity undertaken in small intervals spaced throughout the day can safely and markedly improve the health of people with chronic obstructive pulmonary disease (COPD) and other lung ailments, researchers in Australia reported, based on a review of COPD studies. Dr. Kylie Hill from the Curtin University led the research project,…

Propeller Health has partnered with Aptar Pharma, a drug delivery systems provider, for the development of technology based on metered dose inhaler systems (MDIs) for the treatment of asthma and chronic obstructive pulmonary disease (COPD). Under the terms of the partnership, Propeller and Aptar will work to develop the…

A recent study examined the possible association between more frequent exacerbations in chronic obstructive pulmonary disease (COPD) and stroke, finding no evidence for such a link. The report, “No association between exacerbation frequency and stroke in patients with COPD,“ appeared on Feb. 2, 2016, in the…

A study recently published in the journal Chest found that patients with chronic obstructive pulmonary disease (COPD) had decreased gray matter in cerebral areas that process breathlessness, fear, and pain sensitivity. Intrapulmonary inflammatory processes restrict the flow of air in the lungs of people with COPD, and breathlessness is commonly experienced…

Boehringer Ingelheim Pharmaceuticals, Inc., recently released data showing that Stiolto Respimat (inhalation spray) improved lung function over a range of measures in patients with chronic obstructive pulmonary disease (COPD), when compared to a European formulation of a long-acting beta agonist (salmeterol) and an inhaled corticosteroid (fluticasone propionate). Stiolto Respimat was approved…

Lexington, Massachusetts-based Pulmatrix Inc. is enrolling participants for a European pilot bioequivalence study on its product PUR0200, a bronchodilator for the treatment of chronic obstructive pulmonary disease (COPD). The company expects to finish enrollment by the first quarter of 2016 and report initial results in the second quarter. Pulmatrix says its iSPERSE (inhaled…

In a new study, researchers at the University of Toronto investigated the independent relationship between chronic obstructive pulmonary disorder (COPD) and past-year generalized anxiety disorder (GAD), and found that the prevalence of anxiety is much higher among older adults with COPD than in older adults without the disease. The…